Payment overview · 2025
General Payments
$1,064.78
51 reported records · 16 companies
Healthcare provider profile · identity verified
James B Walsh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MUNSTER, IN · NPI 1619970340
Verified facts
What the public records show
CMS Open Payments records show James B Walsh, MD received $1,064.78 in general payments during 2025 across 51 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $186.66 | 17.5% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $180.20 | 16.9% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.59 | 8.9% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.56 | 8.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.30 | 8.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.98 | 6.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $55.99 | 5.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.69 | 4.7% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.40 | 4.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.68 | 3.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.69 | 3.5% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $37.04 | 3.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.53 | 3.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.69 | 1.9% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $17.19 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.59 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,064.78 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $186.66 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $152.42 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.59 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $92.56 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.43 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.43 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.45 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $55.99 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.40 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.40 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.68 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $38.28 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $37.04 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.53 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| APOLLO ESG System Normalized: apollo esg system |
Device | Boston Scientific Corporation | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 718 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 620 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 122 |
| Losartan Potassium | Losartan Potassium | 431 | 120 |
| Alprazolam | Alprazolam | 394 | 77 |
| Lisinopril | Lisinopril | 351 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 98 |
| Simvastatin | Simvastatin | 291 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 259 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 256 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 72 |
| Omeprazole | Omeprazole | 236 | 68 |
| Furosemide | Furosemide | 235 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 214 | 38 |
| Metformin Hcl | Metformin Hcl | 208 | 60 |
| Gabapentin | Gabapentin | 180 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 45 |
| Lorazepam | Lorazepam | 148 | 29 |
| Allopurinol | Allopurinol | 147 | 44 |
| Potassium Chloride | Potassium Chloride | 147 | 46 |
| Tramadol Hcl | Tramadol Hcl | 134 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 34 |
| Eliquis | Apixaban | 125 | 21 |
| Atenolol | Atenolol | 120 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 32 |
| Glimepiride | Glimepiride | 112 | 27 |
| Montelukast Sodium | Montelukast Sodium | 110 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 39 |
| Carvedilol | Carvedilol | 105 | 31 |
| Metformin Hcl Er | Metformin Hcl | 105 | 28 |
| Sertraline Hcl | Sertraline Hcl | 91 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 26 |
| Azithromycin | Azithromycin | 88 | 68 |
| Jardiance | Empagliflozin | 86 | 20 |
| Synthroid | Levothyroxine Sodium | 85 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 18 |
| Finasteride | Finasteride | 73 | 23 |
| Meloxicam | Meloxicam | 70 | 20 |
| Xarelto | Rivaroxaban | 66 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 19 |
| Cephalexin | Cephalexin | 64 | 41 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 16 |
| Farxiga | Dapagliflozin Propanediol | 64 | 15 |
| Memantine Hcl | Memantine Hcl | 61 | 16 |
| Enalapril Maleate | Enalapril Maleate | 60 | 13 |
| Pregabalin | Pregabalin | 60 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 16 |
| Irbesartan | Irbesartan | 59 | 20 |
| Januvia | Sitagliptin Phosphate | 59 | 17 |
| Benazepril Hcl | Benazepril Hcl | 58 | 14 |
| Clonazepam | Clonazepam | 56 | 11 |
| Meclizine Hcl | Meclizine Hcl | 54 | 18 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Ozempic | Semaglutide | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Donepezil Hcl | Donepezil Hcl | 48 | 16 |
| Ezetimibe | Ezetimibe | 47 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 25 |
| Famotidine | Famotidine | 43 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 13 |
| Warfarin Sodium | Warfarin Sodium | 42 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | 11 |
| Hydrocortisone | Hydrocortisone | 36 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | 14 |
| Premarin | Estrogens, Conjugated | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 21 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Prednisone | Prednisone | 33 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 20 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 23 |
| Temazepam | Temazepam | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Naproxen | Naproxen | 23 | 12 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Colchicine | Colchicine | 16 | 12 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Topiramate | Topiramate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,064.78 · 51 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, AIRSUPRA, APOLLO ESG System, AREXVY, COMIRNATY, Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, LOREEV XR, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VOQUEZNA, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error